5505 MOREHOUSE DRIVE, SAN DIEGO, CA
Director Resignation - Diego Miralles Steps Down; CFO Departure - Thad Huston
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Artiva Biotherapeutics Enters Underwriting Agreement for 23.87M Shares
Reports Full Year 2025 Financial Results and Recent Business Highlights
CFO Appointment - Thad Huston Named Chief Financial Officer
Board Appointment - Elaine Sorg Joins Artiva Biotherapeutics Board
Artiva Biotherapeutics Enters RSU Exchange Agreements with Executives
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Q1
Amended Annual Report
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Certificate
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Free Writing Prospectus
S-1MEF